title: Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
abstract: Cytogenetic abnormalities of chromosome 13 (CA 13) and those detected by fluorescence in situ hybridization (FISH 13) have both been associated with poor prognosis in multiple myeloma (MM) patients. The prognostic implications of CA, FISH 13 and other standard laboratory parameters were examined in the first 231 patients enrolled in Total Therapy II, an intensive cytotoxic chemotherapy programme with tandem autotransplants. Three-year projections of event-free survival (EFS) and overall survival (OS) were 71% and 77% respectively. CA 13 was detected in 14% and significantly correlated with FISH 13 (present in 51%), tumour burden, proliferative activity and lactic dehydrogenase (LDH). Both EFS and OS were significantly shorter in patients with CA 13, FISH 13, LDH >or= 190 U/l, beta2 microglobulin >or= 4 mg/l and C reactive protein >or= 4.0 mg/l; other CA was an additional risk factor for OS. Two-thirds of CA 13 patients were identified by FISH 13 and plasma-cell-labelling index (PCLI) >or= 0.4%; however, PCLI failed to identify additional risk groups in FISH subsets. Although present in considerably fewer patients, CA 13 imparted more rapid relapse (61% at 3 years) and death (43% at 3 years) than FISH 13 (38% and 35%; P = 0.02 and 0.1 respectively) and should be part of the initial work-up of patients with MM.
authors.affiliation: Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. shaughnessyjohn@uams.edu
authors.forename: John
authors.initials: J
authors.lastname: Shaughnessy
authors.forename: Erming
authors.initials: E
authors.lastname: Tian
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Sawyer
authors.forename: Jason
authors.initials: J
authors.lastname: McCoy
authors.forename: Guido
authors.initials: G
authors.lastname: Tricot
authors.forename: Joth
authors.initials: J
authors.lastname: Jacobson
authors.forename: Elias
authors.initials: E
authors.lastname: Anaissie
authors.forename: Maurizio
authors.initials: M
authors.lastname: Zangari
authors.forename: Athanasios
authors.initials: A
authors.lastname: Fassas
authors.forename: Firas
authors.initials: F
authors.lastname: Muwalla
authors.forename: Christopher
authors.initials: C
authors.lastname: Morris
authors.forename: Bart
authors.initials: B
authors.lastname: Barlogie
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002882:Chromosomes, Human, Pair 13; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D017353:Gene Deletion; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007399:Interphase; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D015996:Survival Rate; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide